to us without charge by the Chemotherapy National Service Center, National Cancer Institute. Barbituric acid was obtained from Nutritional Biochemicals Corp.
(Cleveland). 5-AZOA, when used, was present in the medium at a final concentration of 6 X 10-' Ill, and barbituric acid at a final concentration of 1.2 X 10-' ll1. Orotic acid (OA), dihydroorotic acid (DHOA), and ureidosuccinic acid (carbamyl aspartic acid) (US) were obtained from Calbiochem (Los Angeles) and were used at a final concentration of 6 X 10-4 Al. The source of other materials, the composition of the media, and the concentration of other experimental supplements to the medium have been previously described.' llethods.-The assay'0 for dihydroorotase (DHOase) measures the rate at which DHOA accumulates when a cell extract is incubated in the presence of US. The concentration of DHOA is determined from the kinetics of decline of optical density at 240 m/u, following treatment of the reaction mixture with alkali. Other methods used are described in a previous publication.' Preliminary considerations: Site of action of enzyme inhibitors: 6-AZUMP and 5-AZOA are, respectively, competitive inhibitors of yeast O1\IP decarboxylasell and the OMIP pyrophosphorylase activity of intact mammalian cells.'2 We have shown' that 6-AZUM\P has the same action on the OMP decarboxylase recovered from cultured human diploid cells a finding which is consistent with the known metabolic derangements produced by 6-AZUR in whole mammals.'3 Similarly, 5-AZOA can be shown to inhibit the OMP pyrophosphorylase activity in extracts of human diploid cell strains. We presume that the inhibition by 5-AZOA is competitive, though for this analogue we have not directly proven that it is. In addition, we have shown that 6-AZUMP inhibits OMP decarboxylase but not OMP pyrophosphorylase, anId conversely, that 5-AZOA inhibits the pyrophosphorylase but not the decarboxylase (Table 1) .
Barbituric acid is known to be a competitive inhibitor of the dihydroorotic acid dehydrogenase activity recovered from Zymobacterium oroticum. 4 Because we do not yet have a satisfactory assay for this enzyme in extracts of cultured human cells, we cannot directly verify this observation with our material.-The site of action of barbituric acid shown in Figure 1 is the presumptive one.
Results.
-(1) Experiments with 5-AZOA: (a) Growth experiments: At a concentration of 6 X 10-5 M, 5-AZOA has no effect on the growth of cells of either homozygous genotype. 5-AZOA (180 X 10-5 M) measurably slows the growth of both normal and mutant homozygous cells. Moreover, the cells are protected from this growth-inhibiting activity of 5-AZOA if cytidine is also present in the medium.
(b) Effect of growth in 5-AZOA on the specific OMP decarboxylase and OMP pyrophosphorylase activities of the cell protein: As shown in Table 2 , cells of all three genotypes develop augmented levels of activity when they are grown in 5-AZOA. In this case, as in the case of 6-AZUR, the augmentation applies both to OMP decarboxylase and OiMiP pyrophosphorylase. Note that in the presence of 5-AZOA, the mutant homozygous cells had over 250 times the OMP pyrophosphorylase activity of the control cells grown in AC medium without 5-AZOA. The level of activity observed was equal to that of normal cells in AC medium, and represents a complete reversal of cellular phenotype. We have not, however, shown that the assay for this enzyme is linear over so wide a range.
As noted earlier, 5-AZOA did not, at the concentration used to obtain the data in Table 2 , inhibit cell growth even in the absence of cytidine. On the other hand, an equimolar concentration of 6-AZUR completely arrested growth in the absence of cytidine. The concentration of 5-AZOA had to be increased 30-fold before cell growth was affected. These observations indicate that enhancement of enzyme activity is observed even when the degree of enzyme inhibition is insufficient to interfere with cell growth. They are thus consistent with the view that 6-AZUR and 5-AZOA provoke increased activity of OMP decarboxylase and OMP pyrophosphorylase by a mechanism other than cellular depletion of UMP. The relative ineffectiveness of 5-AZOA, as compared to 6-AZUR, in inhibiting growth could be due to a slower rate of entry into the cell. It is also possible that 5-AZOA is, oIn an equimolar basis, a less powerful inhibitor of OMP pyrophosphorylase than 6-AZUR is of OMP decarboxylase. The ability of cells to grow in 5-AZOA, in either case, may reflect a kind of cellular "escape" from the inhibition. In other words, the augmented levels of OMIP pyrophosphorylase which 5-AZOA causes may be sufficient to overcome the enzyme inhibitioii initially produced by the drug at the col1-centration used.
In any event, the fact that 5-AZOA (an inhibitor of OMAP synthesis) strikingly augments the specific activity of the cell protein for both OAMP decarboxylase and OMP pyrophosphorylase suggests that if a precursor of U1\IP is the active compound in the augmentation process, that precursor is probably not OMP. The next precursor examined was OA.
(2) Experiments with barbituric acid: Barbituric acid (1.2 X 10-3 M) had no measurable effect oil the growth of either normal or mutant homozygous cell strains. However, as shown in Tables 3 and 4 , cells of both genotypes developed augmented levels of O1\IP decarboxylase activity when grown in this concentration of barbituric acid. Tables 3 and 4 also reveal that the level of dihydroorotase in both normal and mutant homozygous cells was not affected by barbituric acid. (The experiments in these two tables were not performed on the two genotypes simultaneously, nor were the two genotypes grown in the same lot of medium; hence, the two tables are not directly comparable with one another.)
The fact that cells grown in barbituric acid, a presumed inhibitor of OA biosynthesis, developed augmented levels of OMP decarboxylase suggests that if an active precursor exists, it is not likely to be OA. If one excludes OMP, and OA, the two precursors that remain, and which are peculiar to the UMP pathway, are DHOA and US. Table 5 have been performed. The effect of OA and US has varied from experiment to experiment. In some experiments one or the other of these compounds failed to augment activity. DHOA was the only precursor of the three that has consistently increased OMP decarboxylase activity, and in five of the six experiments, it had the greatest effect. DHOA has now been observed to cause mutant homozygous cells to develop augmented OM\1P decarboxylase activity in a total of ten experiments, including four in which the other precursors were not tested. The augmentation of enzyme activity which was sometimes seen with OA and US may have resulted from their conversion to DHOA. None of these compounds measurably affects enzyme activity when added directly to cell extracts at a final concentration of 6 X 10-4 M.
Discussion.-Human diploid cell strains have previously been shown to develop increased catalytic activity for both OMP decarboxylase and OMP pyrophosphorylase when they are grown in the presence of 6-AZUR.' Three lines of evidence favored the view that 6-AZUR raises activity mainly by causing an accumulation within the cell of one or more precursors of UMP, rather than by depletion of the cellular pool of this nucleotide. First, 6 -AZUR (and the inhibitors subsequently employed) augmented enzyme activity in the presence of cytidine. The concentration of cytidine was equal to that of 6-AZUR, and was sufficient to satisfy completely the nutritional requirement for a pyrimidine ribonucleoside imposed on the cells by 6-AZUR. Second, the two enzyme inhibitors subsequently employed, 5-AZOA and barbituric acid, caused augmentation of enzyme activity at concentrations which did Inot affect cell growth. Third, growth of mutant homozygous cells in adenosine had previously been shown5 to decrease still further their specific OMP decarboxylase activity. Adenosine and some of its derivatives are known to inhibit the aspartate transcarbamylase and DHOase activities of mammalian cells (Fig. 1) .15, 16 Hence, we suspected that adenosine ultimately lowered OMP decarboxylase activity by decreasing the rate of synthesis of a precursor of UMP.
We have therefore used the idea of an accumulated precursor as a working hypothesis, and inquired which (if any) intermediate along the UMIP biosynthetic pathway was the active one. As noted above, both 5-AZOA and barbituric acid had been shown to cause augmentation of enzyme activity. Since 5-AZOA is known to inhibit OMP synthesis and barbituric acid is presumed to inhibit the synthesis of OA, neither of these intermediates of Ui\IP seemed likely to be the precursor of interest. Thus attention was focused on DHOA and US. In experiments in which cells were grown in three precursors of UMP, namely US, DHOA, and OA, only DHOA consistently increased OMP decarboxylase activity when present in the growth medium, and in nearly every experiment it had the largest effect.
Our data thus support the idea that DHOA causes the cell to develop increased catalytic activity for the final two enzymes in the biosynthetic pathway leading to UMP. They are also consistent with the view that, at least in the case of O:\IP decarboxylase, the increased catalytic activity is due to increased enzyme within the cell.' We have not, however, directly proved that the cell accelerates its rate of enzyme synthesis or decelerates its rate of enzyme breakdown; therefore, we are in no position to distinguish between these possibilities. Moreover, we do not yet know that the augmented levels of activity observed in cells grown on the metabolic analogues and the U1\IP precursors are due to the same enzymes as those responsible for the catalytic activities recovered from cells grown on the minimal medium.
In this connection, we should emphasize that although the large effects due to the metabolic analogues have been observed in cells of all three genotypes, the smaller effects due to adenosine and DHOA have been observed only in mutant homozygous cells. It is perfectly possible that the cultured human diploid fibroblasts contain two sets of loci for the enzymes of UMP biosynthesis. One set of loci may make the enzymes normally present in the cell; the other set of loci may be latent. The second, latent set of loci, however, may be responsive to very high levels of DHOA. The mutant homozygous cells might be unable to use the loci which are normally functional. They might then make the enzymes only when DHOA stimulates them to do so, and the residual activity they have in minimal medium could be due to the DHOA which the genetic block causes them to accumulate. On this formulation it might seem that mutant homozygous cells would spontaneously develop normal levels of enzyme activity, and thus correct their own metabolic defect. They need not do so, however. The DHOA which the cell accumulates because of the genetic block may induce only low levels of enzyme activity, which are then sufficient to prevent a further accumulation of DHOA. If such a mechanism were operative, the level of enzyme activity within the cell might oscillate. It might at all times, however, be far below normal and less than the level necessary for rapid growth in a medium free of pyrimidine nucleosides. In any case this theory predicts that mutant homozygous cells will develop proportionately more enzyme than normal cells for a given intracellular level of DHOA (which is suggested by our data). The theory would be further supported if the enzyme activities of cells in which DHOA had accumulated were found to display different properties from those of cells in which it had not accumulated. This last matter is under study.
Neither the mutant gene' 6 nor the metabolic analogues we have employed' affect the specific activity of the cell protein for dihydroorotase (Fig. 1) . These data support the view that in the human cell the final four enzymes along the biosynthetic pathway leading to UMP do not respond concurrently to a single stimulus as they do in E. coli. Rather, the pathway is subdivided into finer units of control. The last one contains at least two but no more than three enzymes. Summary.-Human diploid cell strains grown in the presence of 6-azauridine, and certain other inhibitors of pyrimidine synthesis, develop augmented levels of activity for the final two sequentially acting enzymes in the biosynthetic pathway leading to uridine-5'-monophosphate. Evidence has been presented suggesting that the increase in activity is more likely to be due to the accumulation within the cell of a precursor of uridine-5'-monophosphate than to depletion of the cellular pool of this nueleotide. The data also suggest that the active precursor may be dihydroorotic acid.
